Posters
- Next Generation Therapy : RNA delivery by LentiFlash for an efficient CRISPR/Cas9-mediated gene knockout in Human iPS (EBMT 2023)
- NK cells engineering using advanced Lentiviral Vectors quality and design (EBMT 2023)
- From research to clinical application, a successful and reproducible continuum process for lentiviral vector manufacturing (Advanced Therapies 2023)
- Gene editing on primary & stem cells using LentiFlash RNA delivery approach (ASGCT 2022)
- Efficient & safe delivery of multiple mRNA using non-integrative bacteriophage-chimeric retrovirus-like particles for in vivo application (ASGCT 2022)
- How to label specific cells or tissues in vitro and in vivo ?
- How to follow the cell differentiation process ?
- Large scale production of lentiviral tools
- Need to precisely control gene expression in your cells ?
- Lentiviral vectors with tissue or cell specific promoters
- All-in-one delivery using lentiflash (ESGCT 2019)
- Primary cells and in vivo immunomodulation using LentiFlash®, a chimeric RNA delivery technology designed for clinical applications
- All-in-one Delivery Using LentiFlash® technology, a MS2-chimeric RNA Delivery Tool Designed for Clinical Applications (ASGCT 2019)
- All-in-one delivery of gene-editing system into primary cells and in vivo using LentiFlash®, an MS2-chimeric viral RNA delivery tool designed for clinical applications (ESGCT 2018)
- How to monitor a specific cell state ?
-
Predictive immunotherapy models (Poster AACR 2015)
- Lentiviral Vectors for in Vitro and in Vivo target Validation (Poster SFTCG 2009)
- Generation of primary cells using lentiviral vectors (Poster SBS 2011)
Application notes
-
Custom and premade lentiviral vectors with cell state specific promoters
- Enhance your production efficiency with optimal plasmid ratio
-
Lentiviral vectors with tissue or cell-specific promoters
- Overview of tissue specific promoters available in pre-made products format
-
Differences between lentiviral vectors and LentiFlash particles
-
Large scale production of lentiviral tools
-
Lentiviral vectors with TET-on 3G system
-
Premade lentiviral vectors to label specific cells or tissues
-
Premade lentiviral vectors to follow the cell differentiation pathway
-
Custom and premade lentiviral vectors with cell state specific promoters
Press release
- Communiqué - Flash Therapeutics et la stratégie vaccinale
- Flash Therapeutics presentation
- Press release - Magenta - EN
Technical notes
-
What is LentiFlash?
-
Lentiviral vectors or LentiFlash particles ?
-
Physical properties of fluorescent proteins available with lentiviral particles
-
GMP lentiviral particle manufacturing
End User Rights
-
End User Rights premade lentiviral vectors with Luc
-
End User Rights premade lentiviral vectors NegControl
-
End User Rights premade lentiviral vectors with fluorescent protein under specific promoter
-
End User RightsEnd User Rights premade lentiviral vectors with Luc under specific promoter
-
End User Rights custom lentiviral vectors with TetON3G
-
End User Rights premade lentiviral vectors with fluorescent protein (for products distributed by Vectalys)
-
End User Rights custom LentiFlash
-
End User Rights premade LentiFlash with fluorescent protein
-
End User Rights LentiFlash plasmids
-
End User Rights custom lentiviral vectors
-
End User Rights custom lentiviral vectors with fluorescent protein
-
End User Rights premade lentiviral vectors for gene editing
-
End User Rights premade LentiFlash for gene editing
-
End User Rights premade LentiFlash with Luc
Other
- 01 - Conditions générales de vente - Flash Therapeutics
- 01 - General terms and conditions of sale - Flash Therapeutics
- 02 - Flash Therapeutics Quality Policy
- 02 - Vectalys Quality Policy - transport
- 03 - Material Safety Data Sheet Lentiviral vectors (EN)
- 03 - Material Safety Data Sheet Lentiviral vectors (FR)
- 04 - List of our own publications
- 05 - Patent list that quote Vectalys
- 06 - Why customers prefer Flash Therapeutics lentiviral vectors ?
-
06 - Why customers prefer Vectalys lentiviral vectors ?
-
07 - Non-exhaustive list of cells transduced with almost 100% efficiency